ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Kidney transplantation"

  • 2020 American Transplant Congress

    Treatment of De Novo Renal Transplant Recipients with Calcineurin Inhibitor (CNI)-Free, Belatacept+Everolimus-Based Immunosuppression

    V. R. Peddi1, B. Marder2, L. Gaite3, J. Oberholzer4, R. Goldberg5, T. Pearson6, H. Yang7, L. Allamassey8, S. Gao8, M. Polinsky8, R. N. Formica9

    1California Pacific Medical Center, San Francisco, CA, 2Colorado Kidney Care, Denver, CO, 3Hospital Marqués de Valdecilla, Cantabria, Spain, 4UVA Health, Charlottesville, VA, 5Saint Barnabas Medical Center, Livingston, NJ, 6Emory University School of Medicine, Atlanta, GA, 7UPMC Pinnacle, Harrisburg, PA, 8Bristol-Myers Squibb, Princeton, NJ, 9Yale University School of Medicine, New Haven, CT

    *Purpose: Compared with CNI-based immunosuppression, kidney transplant recipients receiving belatacept-based treatment present with a favorable metabolic profile, reduced chronic allograft nephropathy, and improved renal function,…
  • 2020 American Transplant Congress

    Outcome after Kidney Transplantation in Hepatitis Surface Antigen-Positive Patients

    H. Mo, S. Min, H. Ko, C. Chung, H. Kim, A. Han, J. Ha

    Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of

    *Purpose: Because of the low prevalence of Hepatitis Surface Antigen (HBsAg)-positive patients, only a few reports have evaluated the actual outcome of these patients after…
  • 2020 American Transplant Congress

    Morbid Obesity: A Growing Barrier to Early Kidney Transplant Wait-Listing in the United States

    L. Lavenburg1, E. Weinhandl2, L. Robinson3, B. Milliron4, C. Earthman5, A. Klassen3, M. Harhay6

    1University of Pennsylvania, Philadelphia, PA, 2Fresenius Medical Care North America, Minneapolis, MN, 3Drexel University Dornsife School of Public Health, Philadelphia, PA, 4Drexel University College of Nursing and Health Professions, Philadelphia, PA, 5University of Delaware, Newark, DE, 6Drexel University College of Medicine, Philadelphia, PA

    *Purpose: Kidney transplant (KT) programs may be more reluctant to accept transplant candidates with morbid obesity due to concerns about higher post-operative risks. We examined…
  • 2020 American Transplant Congress

    Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received

    M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan

    Cedars-Sinai, Los Angeles, CA

    *Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…
  • 2020 American Transplant Congress

    The Challenge of Selecting an Induction Agent: A Dual Regimen for Medically High-Risk Kidney Recipients

    R. Craig-Schapiro, B. Magaoay, R. Grover, S. Sultan, M. Aull, S. Kapur

    Weill Cornell Medical Center, New York, NY

    *Purpose: Complications of the commonly used lymphocyte-depleting induction agent, rabbit anti-thymocyte globulin (rATG),include cardiorespiratory dysfunction with hypotension, tachycardia, myocardial infarction, and pulmonary edema. The choice…
  • 2020 American Transplant Congress

    The Impact of Increased Visceral Fat in Kidney Transplant Recipients

    Y. Miyauchi, T. Noda, N. Miura, T. Kikugawa, T. Saika

    Ehime University, Toon, Japan

    *Purpose: An increased amount of visceral fat (VF) has been reported as a precursor to metabolic syndrome and is a risk factor for renal dysfunction.…
  • 2020 American Transplant Congress

    Long-Term Outcome of Kidney Transplantation for IgA Nephropathy: A Single-Center Experiences

    M. Tasaki1, K. Saito1, Y. Nakagawa2, N. Imai3, Y. Ito3, K. Takahashi4, Y. Tomita1

    1Division of Urology, Department of Regenerative & Transplant, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Division of Urology, Juntendo University, Tokyo, Japan, 3Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 4Otsukadai Clinic, Tokyo, Japan

    *Purpose: Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide, with a high recurrence rate after kidney transplantation (KTx). The aim of this…
  • 2020 American Transplant Congress

    Ehrlichiosis Infection Presenting as Thrombotic Microangiopathy Early after Kidney Transplantation

    W. Hassan1, M. Talwar2, V. Balaraman2, B. Wall1, M. Molnar1

    1Medicine-Nephrology, University of Tennessee Health Science Center, Memphis, TN, 2Department of Surgery, Transplant Surgery, Methodist University Hospital, James D Eason Transplant Institute, Memphis, TN

    *Purpose: Fever of unknown origin and clinical picture of Thrombotic MicroAngiopathy (TMA) are diagnostic challenges in the early period after kidney transplantation. Here we present…
  • 2020 American Transplant Congress

    80 is the New 60: A Single-Center Outcome Study of Octogenarian Kidney Transplant Recipients

    D. Shankaranarayanan, T. Muthukumar, S. Sultan, A. Watkins, D. Serur, C. Hartono

    Weill Cornell Medicne, New York City, NY

    *Purpose: Kidney transplantation is the treatment of choice for end stage renal disease. However, limited data is available on the outcomes of octogenarian recipients.*Methods: Retrospective…
  • 2020 American Transplant Congress

    Autophagy Attenuates Renal Allograft Interstitial Fibrosis by Regulating the EndMT Induced by TNF-α

    Z. Gui, C. Suo, Z. Wang, S. Fei, Z. Han, J. Tao, H. Chen, L. Sun, X. Ju, R. Tan, M. Gu

    Jiangsu Province Hospital, Nanjing, China

    *Purpose: Kidney interstitial fibrosis is a significant cause of allograft failure in kidney transplantation. Autophagy is a self-digestive process that eliminates impaired or aged proteins…
  • « Previous Page
  • 1
  • …
  • 133
  • 134
  • 135
  • 136
  • 137
  • …
  • 531
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences